Health Canada Approves WYNZORA for Psoriasis Treatment

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.1

On December 18, 2025, Knight Therapeutics announced that Health Canada has approved WYNZORA, a new treatment for Psoriasis Vulgaris, a common autoimmune condition characterized by the rapid growth of skin cells leading to scaling, inflammation, and discomfort.

The approval of WYNZORA marks a significant advancement in the management of Psoriasis Vulgaris, posing as an innovative therapeutic option for patients. This treatment specifically addresses the need for effective and safe solutions in the realm of dermatology, where patients often face chronic challenges.

Psoriasis Vulgaris affects millions worldwide, and existing treatments can sometimes fall short in efficacy or have undesirable side effects. The launch of WYNZORA provides hope for both patients and healthcare professionals seeking improved management strategies.

WYNZORA is expected to provide a top-tier treatment option, focusing on minimizing adverse effects while maximizing the therapeutic benefits. Knight Therapeutics is committed to enhancing patient care and believes that this approval will play a crucial role in transforming treatment approaches.

The company plans to make WYNZORA available in the Canadian market shortly, collaborating with healthcare providers to ensure that patients have access to this innovative medication. This underscores Knight Therapeutics’ dedication to patient accessibility and resource optimization in the treatment of chronic conditions.

Overall, the introduction of WYNZORA is a pivotal moment in the dermatology landscape, promising to enhance the quality of life for those battling Psoriasis Vulgaris, which has been a significant concern in public health.